UBS Group
JSPR icon

UBS Group’s Jasper Therapeutics JSPR Stock Holding History

UBS Group’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.7K Sell
58,759
-22,358
-28% -$16.7K ﹤0.01% 8027
2026
Q1 		$71.1K Sell
81,117
-45,244
-36% -$62.8K ﹤0.01% 7180
2025
Q4 		$231K Buy
126,361
+87,007
+221% +$175K ﹤0.01% 6499
2025
Q3 		$93.7K Sell
39,354
-376,921
-91% -$1.14M ﹤0.01% 7164
2025
Q2 		$2.31M Sell
416,275
-118,361
-22% -$583K ﹤0.01% 4660
2025
Q1 		$2.3M Buy
534,636
+370,321
+225% +$2.46M ﹤0.01% 4592
2024
Q4 		$3.51M Buy
164,315
+158,998
+2,990% +$3.31M ﹤0.01% 4180
2024
Q3 		$100K Buy
5,317
+1,265
+31% +$25.2K ﹤0.01% 6371
2024
Q2 		$92K Buy
+4,052
New +$97.2K ﹤0.01% 6229
2023
Q1 		– Sell
-21,552
Closed -$103K – 9976
2022
Q4 		$103K Buy
21,552
+2,749
+15% +$18.4K ﹤0.01% 6065
2022
Q3 		$148K Buy
18,803
+18,249
+3,294% +$334K ﹤0.01% 5365
2022
Q2 		$11K Buy
+554
New +$15.8K ﹤0.01% 7817
2022
Q1 		– Sell
-255
Closed -$20K – 10579
2021
Q4 		$20K Buy
255
+201
+372% +$18.8K ﹤0.01% 7839
2021
Q3 		$6K Sell
54
-123
-69% -$12.6K ﹤0.01% 8427
2021
Q2 		$18K Buy
177
+44
+33% +$4.37K ﹤0.01% 7447
2021
Q1 		$13K Sell
133
-352
-73% -$35.8K ﹤0.01% 7737
2020
Q4 		$49K Buy
485
+419
+635% +$41.7K ﹤0.01% 6199
2020
Q3 		$7K Sell
66
-114
-63% -$11.4K ﹤0.01% 7118
2020
Q2 		$18K Buy
180
+40
+29% +$3.91K ﹤0.01% 6620
2020
Q1 		$13K Buy
+140
New +$13.7K ﹤0.01% 6773

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's JSPR Position: Q2 2026 in Review

UBS Group reduced its Jasper Therapeutics (JSPR) stake by 28% in Q2 2026, selling an estimated $16.7K and leaving 58,759 shares worth $24.7K. The position accounts for ﹤0.01% of the portfolio, ranked #8027.

UBS Group first reported a position in JSPR in Q1 2020 and has held it in 20 quarters since. The position peaked at $3.51M in Q4 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • UBS Group held 58,759 shares of Jasper Therapeutics worth $24.7K as of Q2 2026.
  • UBS Group sold 22,358 Jasper Therapeutics shares in Q2 2026, an estimated $16.7K.
  • Jasper Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8027 holding.
  • UBS Group first reported a position in Jasper Therapeutics in Q1 2020 and has held it in 20 quarters since.
  • UBS Group's Jasper Therapeutics position peaked at $3.51M in Q4 2024.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.